a test drug that destroys the tumor without surgery or chemo

Among all rectal cancerscorpse adenocarcinomas are the most common. To treat them, the cancerologists usually offer surgery to remove the cancerous area, followed by a chemotherapy. Moreover, meimmunotherapy could well replace what protocol heavy for patients. Actually, a small clinical trial made au Sloane Kettering Memorial Cancer Center in New York gave impressive results: 100% of patients were in forgivenesswithout the need for surgery or chemotherapy after treatment by a antibodies dostarlimab.

100% remission

Tested on a small cohort of twelve patients with phase II or III rectal adenocarcinoma, dostarlimab has been able to tumor after an injection every three weeks for six months. In 100% of patients, the tumor was undetectable at SCANNERto MRI, toendoscopy and in biopsies rectal. It does not need surgery or chemotherapy to complete the action of dostarlimab. No patients relapsed in follow-up time, which lasted 6 to 25 months. Dostarlimab did not cause any serious side effects in most patients, only rash, fatigue, nausea and pruritus. Only one person developed a thyroid problem that did not endanger their life.

Le dostarlimab is also a spirit for those affected syndrome Lynch – eight of the twelve participants in theclinical trials. This hereditary disease drastically increases the risks of developing a cancer lifelong colorectal cancer, and is associated with poorer results after surgery or anti-cancer chemotherapy. IT’immunotherapy could be a promising tool for treating patients with Lynch syndrome.

Sustainable results?

This approach only works on cancers rectum the so-called deficits of theDNA, which accounts for 10 to 15% of rectal adenocarcinomas diagnosed each year. Le dostarlimab is an antibody that prevents the recognition of the PD-1 receptor on the lesion lymphocytes T, with the son ligand PDL-1, located on cancer cells. The interaction of the receptor with its ligand paralyzes the immune responseinstead of destroying the abnormal cell, T lymphocyte saves it. By mechanically blocking this interaction, dosarlimab allows lymphocytes to destroy abnormal cells.

Impressive results that will need to be replicated in future independent clinical trials involving more participants. To the question from durability results will also be crucial; if the participants are in remission for several months, do not allow yourself to be told that on that day they will always be in several years.

Interested in what you just read?


Leave a Comment